NexGard Combo

Country: European Union

Language: Danish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

eprinomectin, esafoxolaner, praziquantel

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QP54AA54

INN (International Name):

esafoxolaner, eprinomectin, praziquantel

Therapeutic group:

Katte

Therapeutic area:

Eprinomectin, combinations, , Avermectins, Antiparasitic products, insecticides and repellents

Therapeutic indications:

For cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. Det veterinære lægemidler produkt er udelukkende angivet, når alle tre grupper er målrettet på samme tid.

Product summary:

Revision: 1

Authorization status:

autoriseret

Authorization date:

2021-01-06

Patient Information leaflet

                                19
B. INDLÆGSSEDDEL
20
INDLÆGSSEDDEL:
NEXGARD COMBO, SPOT-ON, OPLØSNING TIL KATTE < 2,5 KG
NEXGARD COMBO, SPOT-ON, OPLØSNING TIL KATTE 2,5-7,5 KG
1.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
SAMT PÅ DEN INDEHAVER AF VIRKSOMHEDSGODKENDELSE, SOM ER
ANSVARLIG FOR BATCHFRIGIVELSE, HVIS FORSKELLIG HERFRA
Indehaver af markedsføringstilladelsen:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
Tyskland
Fremstiller ansvarlig for batchfrigivelse:
Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 Toulouse
Frankrig
2.
VETERINÆRLÆGEMIDLETS NAVN
NexGard Combo, spot-on opløsning til katte < 2,5 kg
NexGard Combo, spot-on opløsning til katte 2,5-7,5 kg
esafoxolaner, eprinomectin, praziquantel
3.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
Hver spot-on applikator indeholder:
AKTIVE STOFFER:
NexGard Combo
Indhold pr.
dosisenhed (ml)
Esafoxolaner
(mg)
Eprinomectin
(mg)
Praziquantel
(mg)
Katte 0,8-<2,5 kg
0,3
3,60
1,20
24,90
Katte 2,5-<7,5 kg
0,9
10,80
3,60
74,70
HJÆLPESTOFFER:
Butylhydroxytoluen (E321) 1 mg/ml.
Spot-on, opløsning.
Klar, farveløs til lys gul til lys brun opløsning.
4.
INDIKATIONER
Til katte som har eller risikerer at få blandingsinfektioner med
cestoder, nematoder og ektoparasitter.
Veterinærlægemidlet skal udelukkende anvendes, når der behandles
samtidigt for alle tre grupper.
Ektoparasitter
-
Behandling af loppeangreb (
_Ctenocephalides felis_
). En behandling giver øjeblikkelig
loppedræbende virkning som varer i en måned.
-
Præparatet kan indgå som led i behandlingen af loppebetinget
allergisk dermatit (FAD).
-
Behandling af flåtangreb. En behandling giver øjeblikkelig og
vedvarende dræbende virkning
over for
_Ixodes scapularis_
i en måned og over for
_Ixodes ricinus_
i fem uger.
21
-
Behandling af angreb af øremider (
_Otodectes cynotis_
).
-
Behandling af notoedric skab hos kat (forårsaget af
_Notoedres cati_
).
Cestoder
Behandling af infektioner med bændelorm (
_Dipylidium caninum, Taenia taeniaeformis, Echinococc
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
BILAG I
PRODUKTRESUME
2
1.
VETERINÆRLÆGEMIDLETS NAVN
NexGard Combo, spot-on, opløsning til katte < 2,5 kg
NexGard Combo, spot-on, opløsning til katte 2,5-7,5 kg
2.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING
AKTIVE STOFFER:
Hver spot-on applikator indeholder:
NexGard Combo
Indhold pr.
dosisenhed (ml)
Esafoxolaner
(mg)
Eprinomectin
(mg)
Praziquantel
(mg)
Katte 0,8-<2,5 kg
0,3
3,60
1,20
24,90
Katte 2,5-<7,5 kg
0,9
10,80
3,60
74,70
HJÆLPESTOFFER:
Butylhydroxytoluen (E321) 1 mg/ml.
Alle hjælpestoffer er anført under pkt. 6.1.
3.
LÆGEMIDDELFORM
Spot-on, opløsning.
Klar, farveløs til lys gul til lys brun opløsning.
4.
KLINISKE OPLYSNINGER
4.1
DYREARTER, SOM LÆGEMIDLET ER BEREGNET TIL
Katte.
4.2
TERAPEUTISKE INDIKATIONER MED ANGIVELSE AF DYREARTER, SOM LÆGEMIDLET
ER BEREGNET TIL
Til katte som har eller risikerer at få blandingsinfektioner med
cestoder, nematoder og ektoparasitter.
Veterinærlægemidlet er udelukkende indiceret, når der behandles
samtidigt for alle tre grupper.
Ektoparasitter
-
Behandling af loppeangreb (
_Ctenocephalides felis_
). En behandling giver øjeblikkelig
loppedræbende virkning, som varer i en måned.
-
Præparatet kan indgå som led i behandlingen af loppebetinget
allergisk dermatit (FAD).
-
Behandling af flåtangreb. En behandling giver øjeblikkelig og
vedvarende dræbende virkning
over for
_Ixodes scapularis_
i en måned og over for
_Ixodes ricinus_
i fem uger.
-
Behandling af angreb af øremider (
_Otodectes cynotis_
).
-
Behandling af notoedric skab (kattens skabmide) (forårsaget af
_Notoedres cati_
).
Gastrointestinale cestoder
-
Behandling af infektioner med bændelorm (
_Dipylidium caninum, Taenia taeniaeformis, _
_Echinococcus multilocularis, Joyeuxiella pasqualei_
og
_Joyeuxiella fuhrmanni_
).
3
Nematoder
Gastrointestinale nematoder
-
Behandling af infektioner med gastrointestinale nematoder (L3, L4
larver og voksne stadier af
_Toxocara cati_
, L4 larver og voksne stadier af
_Ancylostoma tubaeforme_
og
_Ancylostoma _
_ceylanicum_
samt voksne stadier af
_Toxascaris leo
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-02-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-02-2022
Public Assessment Report Public Assessment Report Bulgarian 16-02-2022
Patient Information leaflet Patient Information leaflet Spanish 16-02-2022
Public Assessment Report Public Assessment Report Spanish 16-02-2022
Patient Information leaflet Patient Information leaflet Czech 16-02-2022
Public Assessment Report Public Assessment Report Czech 16-02-2022
Patient Information leaflet Patient Information leaflet German 16-02-2022
Public Assessment Report Public Assessment Report German 16-02-2022
Patient Information leaflet Patient Information leaflet Estonian 16-02-2022
Public Assessment Report Public Assessment Report Estonian 16-02-2022
Patient Information leaflet Patient Information leaflet Greek 16-02-2022
Public Assessment Report Public Assessment Report Greek 16-02-2022
Patient Information leaflet Patient Information leaflet English 16-02-2022
Public Assessment Report Public Assessment Report English 16-02-2022
Patient Information leaflet Patient Information leaflet French 16-02-2022
Public Assessment Report Public Assessment Report French 16-02-2022
Patient Information leaflet Patient Information leaflet Italian 16-02-2022
Public Assessment Report Public Assessment Report Italian 16-02-2022
Patient Information leaflet Patient Information leaflet Latvian 16-02-2022
Public Assessment Report Public Assessment Report Latvian 16-02-2022
Patient Information leaflet Patient Information leaflet Lithuanian 16-02-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-02-2022
Public Assessment Report Public Assessment Report Lithuanian 16-02-2022
Patient Information leaflet Patient Information leaflet Hungarian 16-02-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 16-02-2022
Public Assessment Report Public Assessment Report Hungarian 16-02-2022
Patient Information leaflet Patient Information leaflet Maltese 16-02-2022
Public Assessment Report Public Assessment Report Maltese 16-02-2022
Patient Information leaflet Patient Information leaflet Dutch 16-02-2022
Public Assessment Report Public Assessment Report Dutch 16-02-2022
Patient Information leaflet Patient Information leaflet Polish 16-02-2022
Public Assessment Report Public Assessment Report Polish 16-02-2022
Patient Information leaflet Patient Information leaflet Portuguese 16-02-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 16-02-2022
Public Assessment Report Public Assessment Report Portuguese 16-02-2022
Patient Information leaflet Patient Information leaflet Romanian 16-02-2022
Public Assessment Report Public Assessment Report Romanian 16-02-2022
Patient Information leaflet Patient Information leaflet Slovak 16-02-2022
Public Assessment Report Public Assessment Report Slovak 16-02-2022
Patient Information leaflet Patient Information leaflet Slovenian 16-02-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 16-02-2022
Public Assessment Report Public Assessment Report Slovenian 16-02-2022
Patient Information leaflet Patient Information leaflet Finnish 16-02-2022
Public Assessment Report Public Assessment Report Finnish 16-02-2022
Patient Information leaflet Patient Information leaflet Swedish 16-02-2022
Public Assessment Report Public Assessment Report Swedish 16-02-2022
Patient Information leaflet Patient Information leaflet Norwegian 16-02-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 16-02-2022
Patient Information leaflet Patient Information leaflet Icelandic 16-02-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 16-02-2022
Patient Information leaflet Patient Information leaflet Croatian 16-02-2022
Public Assessment Report Public Assessment Report Croatian 16-02-2022

View documents history